CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 109 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2021. The put-call ratio across all filers is 0.33 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $4,718,769 | -36.2% | 111,634 | -36.0% | 0.01% | -28.6% |
| Q4 2023 | $7,398,715 | +450.4% | 174,498 | +183.4% | 0.01% | +600.0% |
| Q3 2023 | $1,344,160 | -41.9% | 61,574 | -15.4% | 0.00% | -50.0% |
| Q2 2023 | $2,313,454 | +71.0% | 72,773 | +31.2% | 0.00% | +100.0% |
| Q1 2023 | $1,352,888 | -22.6% | 55,469 | +0.0% | 0.00% | -50.0% |
| Q4 2022 | $1,748,956 | +23.6% | 55,452 | +10.8% | 0.00% | 0.0% |
| Q3 2022 | $1,415,000 | +10.3% | 50,036 | +3.2% | 0.00% | +100.0% |
| Q2 2022 | $1,283,000 | -0.6% | 48,503 | +31.5% | 0.00% | 0.0% |
| Q1 2022 | $1,291,000 | +24.5% | 36,881 | +15.4% | 0.00% | 0.0% |
| Q4 2021 | $1,037,000 | +27.9% | 31,961 | +16.2% | 0.00% | – |
| Q3 2021 | $811,000 | +107.4% | 27,497 | +80.2% | 0.00% | – |
| Q2 2021 | $391,000 | +119.7% | 15,262 | +17.9% | 0.00% | – |
| Q1 2021 | $178,000 | – | 12,947 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 65,679,781 | $2,685,646,245 | 57.02% |
| Twin Securities, Inc. | 416,657 | $17,037,105 | 13.40% |
| Sand Grove Capital Management LLP | 919,023 | $37,578,850 | 10.99% |
| Perceptive Advisors | 10,794,876 | $441,402,480 | 10.63% |
| P SCHOENFELD ASSET MANAGEMENT LP | 796,440 | $32,566,432 | 7.87% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,353,694 | $96,242,547 | 4.60% |
| Avoro Capital Advisors LLC | 7,539,547 | $308,292,077 | 4.11% |
| Melqart Asset Management (UK) Ltd | 1,099,229 | $44,947,474 | 3.72% |
| Paradigm Biocapital Advisors LP | 2,330,508 | $95,294,472 | 3.65% |
| WATER ISLAND CAPITAL LLC | 766,933 | $31,360 | 3.33% |